Sansheng Pharmaceutical monoclonal antibody injection (608) clinical trial application approved

Recently, China's leading bio
pharmaceutical(http://company(http://Sansheng Pharmaceuticals (01530HK) announced that its self-developed redeveloped recombinant humanized anti-white-17A monoclonal antibody injection (608) has submitted to the NationalDrug(http://Regulatory Authority an application for clinicaltrial(http://The approved 608 of the indications were severe plaque-like psoriasisIn recent years, the harm of psoriasis has been paid more and more attention by the medical communityStudies have shown that nearly 30% of psoriasis patients may develop psoriasis arthritis (PsA)PsA joint sill can cause pain, stiffness and other discomfort symptoms, some patients may even appear irreversible joint damage, resulting in joint deformation and disability 　　Psoriasis is also often associated with other diseases, such as diabetes, heart disease and depression, which seriously affect the patient's physical, mental and physical health
(http:// and quality of life The approved 608 product (http:// will hopefully provide more treatment options for psoriasis patients 　　About 608
608 is a recombinant humanized anti-whitemele-17A monoclonal antibody, which uses DNA recombination techniques to express it in Chinese hamster ovary cells (CHO) for the treatment of moderately severe plaque-like psoriasis 　　About Sansheng Pharmaceuticals Sansheng Pharmaceuticals is a comprehensive biotechnology company with a market-leading biopharmaceutical business covering the therapeutic areas of oncology, autoimmune diseases, kidney disease, metabolic diseases, dermatology, etc 　　Sansheng Pharmaceuticals is committed to building an innovative product pipeline, and more than 30 candidate products are currently under development Sansheng Pharmaceuticals has the capability to produce monoclonal antibodies, recombinant proteins and chemical synthetic (http:// molecular products, with research and development and production centers in Shenyang, Shanghai, Hangzhou, Shenzhen and Como, Italy